证券研究报告 | 公司动态点评 2025 年 08 月 20 日 广誉远（600771.SH） 25H1 营收净利双增长，国企改革成效显现 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 1,284 | 1,221 | 1,440 | 1,674 | 1,936 | | 增长率 yoy（%） | 13.6 | -4.9 | 17.9 | 16.2 | 15.6 | | 归母净利润（百万元） | 90 | 74 | 136 | 156 | 188 | | 增长率 yoy（%） | 136.0 | -17.3 | 82.6 | 14.8 | 20.4 | | ROE（%） | 6.2 | 5.3 | 8.5 | 8.9 | 9.7 | | EPS 最新摊薄（元） | 0.18 | 0.15 | 0.28 | 0.32 | 0.38 | | P/E（倍） | 116.7 | 141.2 | 77.3 | 67.3 | 55.9 | | P/B（倍） | 7.0 | ...

广誉远中药股份有限公司2025 年半年度报告 公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 二○二五年八月十九日 广誉远中药股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人李晓军、主管会计工作负责人王俊波及会计机构负责人（会计主管 人员）付守军声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质 承诺，敬请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完 整性 否 十、 重大风险提示 报告期内，不存在对公司生产经营产生实 ...

Core Viewpoint - GuangYuYuan Chinese Herbal Medicine Co., Ltd. is preparing for its 2024 annual shareholders' meeting, focusing on maintaining shareholder rights and ensuring efficient proceedings [1][2][3]. Meeting Arrangements - The annual shareholders' meeting is scheduled for June 24, 2025, at 14:00 in Taiyuan, Shanxi [3]. - Shareholders must arrive 30 minutes early for registration and are limited to three minutes for speaking [2][3]. - Voting will occur both on-site and through internet platforms during specified time slots [3]. Agenda Items - The meeting will cover several key reports, including the 2024 annual work report from the board of directors, the supervisory board's report, financial statements, profit distribution plans, and independent directors' reports [3][4][5]. Board of Directors' Report - The board held six meetings during the reporting period, addressing various operational and financial matters, including accounting errors and annual reports [6][7]. - The company reported total assets of 2.276 billion and net assets of 1.570 billion as of December 31, 2024, with a revenue of 1.221 billion, a decrease of 4.87% year-on-year [13]. Operational Focus - The company emphasizes growth and operational efficiency, focusing on four core products and expanding its market presence through partnerships and new store openings [13][14]. - A cultural heritage strategy is in place to enhance brand influence, including collaborations with educational institutions and media [14][15]. Quality Assurance - The company is committed to high-quality production standards, implementing a comprehensive quality management system and collaborating with research institutions for innovation [15][16][20]. Governance and Compliance - The company is enhancing its governance structure, focusing on compliance and risk management, and has revised various internal regulations to ensure transparency and accountability [17][22][27]. Future Strategy - The company aims to strengthen its market position by leveraging its historical and cultural assets, enhancing brand visibility, and driving innovation through technology [19][21][22].

Group 1 - The company has shifted its management approach from "strong control" to "strong operation," emphasizing growth as the primary goal and enhancing operational efficiency [2] - Recent management adjustments have led to a consensus on promoting growth, resulting in improved decision-making and sales performance across various product lines [2] - The company has successfully navigated economic downturns and industry pressures by leveraging strong product efficacy and effective marketing strategies [2] Group 2 - All four core products and business divisions have shown growth, with the An Gong series stabilizing after a decline in 2024, and the Gui Ling Gao regaining its status as a core product [2] - The company is actively addressing the impact of healthcare policies on its products, particularly focusing on optimizing product strategies and enhancing market research [2] - Brand promotion efforts are being intensified through collaborations with authoritative media and research institutions, aiming to enhance marketing effectiveness and academic support for products [2] Group 3 - The company is focused on improving operational quality and market share, with internal performance metrics aligned with growth objectives [3] - The company has established a market value management system in response to regulatory requirements, emphasizing communication with investors and proactive management of stock price fluctuations [3]

Group 1 - The core viewpoint of the collaboration between Guangyuyuan and Zhongkang Technology is to enhance brand value, market insights, and product innovation in the high-end traditional Chinese medicine sector [1][3] - The meeting emphasized the importance of cultural empowerment and data-driven strategies to position Guangyuyuan among the top tier of high-end traditional Chinese medicine brands [1][3] - The collaboration aims to leverage Zhongkang Technology's strengths in data analysis and resource integration to optimize product distribution and enhance operational efficiency [3][4] Group 2 - The traditional Chinese medicine market is shifting towards rational and quality-focused consumption, creating opportunities for high-quality brands like Guangyuyuan [3] - Guangyuyuan, with nearly 500 years of history, aims to reconstruct its brand value by focusing on cultural heritage and modern health needs [3][4] - The partnership will explore innovative expressions of traditional Chinese medicine culture, enhancing consumer awareness of heritage craftsmanship [4]

Company Performance - Guangyuyuan achieved an operating income of 1.22 billion yuan and a net profit attributable to shareholders of 74.45 million yuan for the year 2024 [1] - In Q1 2025, the company reported an operating income of 417 million yuan, a year-on-year increase of 21.48%, and a net profit of 63.58 million yuan, up 53.94% year-on-year [1] Industry Overview - The pharmaceutical manufacturing industry in China has shown signs of transformation driven by policy changes and market demand, with total operating income for 2024 at 25,298.5 billion yuan, remaining stable compared to 2023 [2] - The total profit for the pharmaceutical manufacturing industry in 2024 was 342.07 billion yuan, reflecting a year-on-year decline of 1.1%, although the rate of decline has slowed [2] - The traditional Chinese medicine sector is recovering growth due to government support and external factors such as an aging population and increased health demands [2] R&D and Innovation - Guangyuyuan has a history of 484 years and is recognized as a "Chinese Time-honored Brand," with key products included in national and provincial intangible cultural heritage lists [3] - The company increased its R&D expenditure to 38.59 million yuan in 2024, a 22.98% increase from the previous year, focusing on key products to enhance competitiveness [3] - Guangyuyuan is committed to a dual-driven development model of inheritance and innovation, collaborating with research institutions to create profitable research outcomes [3] Marketing Strategy - There is a growing demand for traditional Chinese medicine for health maintenance, with Guangyuyuan's products targeting specific consumer groups, indicating potential growth in the outpatient market [4] - The company has deepened strategic partnerships with top-tier chains and expanded its marketing channels, leading to significant growth in sales revenue [4] - Guangyuyuan has established a digital economy division to enhance online sales channels, adapting to new consumer trends and creating a strong competitive advantage [4]